BioDelivery Sciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference.

RALEIGH, N.C. -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today that Dr. Mark A. Sirgo, President & Chief Executive Officer, will be presenting at the Lazard Capital Markets 6th Annual Healthcare Conference to be held November 17-18, 2009, at The St. Regis Hotel, New York.

BioDelivery Sciences' presentation is scheduled for Tuesday, November 17, at 4:10 PM Eastern Time.

Dr. Sirgo will be providing an update on the October 2009 commercial launch of ONSOLIS (fentanyl buccal soluble film) as well as an update on BDSI's product pipeline, which includes BEMA Buprenorphine and two additional BEMA-formulated product candidates recently added to the portfolio. Dr. Sirgo will also discuss anticipated Company milestones for the remainder of 2009 and those expected to occur in 2010.

The presentation will be webcast live and can be accessed at www.biodeliverysciences.com. For those who are not available to listen to the live broadcast, the presentation will be archived.

About BioDelivery Sciences International

BioDelivery Sciences (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet needs in the areas of pain management and oncology supportive care. BDSI's pain franchise currently consists of two products utilizing the Company's patented BEMA buccal soluble film technology: ONSOLIS (fentanyl buccal soluble film) which was approved by FDA on July 16, 2009, for the management of breakthrough pain in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain, and BEMA Buprenorphine, an analgesic in Phase 2 clinical development with at least one potential target indication for the treatment of moderate to severe pain. Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting and migraine. The Company is also working with its patented Bioral cochleate technology to facilitate oral dosing of drugs otherwise given by intravenous administration. The first product under development using the technology is Bioral Amphotericin B. The Company's headquarters is located in Raleigh, North Carolina. For more information please visit www.biodeliverysciences.com.

BDSI([R]), BEMA([R]) and Bioral([R]) are registered trademarks, and ONSOLIS(TM) is a trademark of BioDelivery Sciences International, Inc.

Cautionary Note on Forward-Looking Statements

This press release and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).